Recurrence of Bladder Cancer After Transurethral Resection With Hexvix
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Rate of bladder cancer recurrence
12 Months
No
Jean-Paul Antonini
Study Director
GE Healthcare
United Kingdom: Medicines and Healthcare Products Regulatory Agency
GE-196-001
NCT00785694
December 2008
August 2011
Name | Location |
---|